109 related articles for article (PubMed ID: 14981100)
1. Prophylactic oophorectomy and hormone replacement therapy: protection at what price?
Garber JE; Hartman AR
J Clin Oncol; 2004 Mar; 22(6):978-80. PubMed ID: 14981100
[No Abstract] [Full Text] [Related]
2. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
Biglia N; Mariani L; Ponzone R; Sismondi P
Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
[No Abstract] [Full Text] [Related]
4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
6. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
7. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
[No Abstract] [Full Text] [Related]
8. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
[TBL] [Abstract][Full Text] [Related]
9. Socio-demographic and clinical profile of BRCA1/2 mutation carriers opting for prophylactic oophorectomy.
Dagan E; Gil S; Gershoni-Baruch R
Prev Med; 2008 May; 46(5):470-2. PubMed ID: 18255133
[No Abstract] [Full Text] [Related]
10. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
11. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Powell CB
Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
[No Abstract] [Full Text] [Related]
12. Preventive gynecologic surgery for BRCA1/2 carriers--information for decision-making.
Quillin JM; Boardman CH; Bodurtha J; Smith T
Gynecol Oncol; 2001 Oct; 83(1):168-70. PubMed ID: 11585435
[No Abstract] [Full Text] [Related]
13. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
14. Quality or quantity in the management of hereditary ovarian cancer risk: Is it really a trade-off?
Masciari S; Garber JE
J Clin Oncol; 2005 Oct; 23(28):6817-9. PubMed ID: 16157931
[No Abstract] [Full Text] [Related]
15. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy.
ACOG
Obstet Gynecol; 2008 Jan; 111(1):231-41. PubMed ID: 18165419
[No Abstract] [Full Text] [Related]
16. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Lubsen-Brandsma L; Massuger LF; Mourits MJ; Gaarenstroom KN; van Dorst EB; van der Putten H; Boonstra H; Aaronson NK
J Clin Oncol; 2007 Jan; 25(3):301-7. PubMed ID: 17235045
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Mahajan NN
Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
[No Abstract] [Full Text] [Related]
18. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
19. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
Agnantis NJ; Paraskevaidis E; Roukos D
Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
[No Abstract] [Full Text] [Related]
20. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
